Neuren Pharmaceuticals (ASX:NEU) Reports Q2 2025 DAYBUE Sales Growth
Financial Performance
Neuren Pharmaceuticals reported Q2 2025 DAYBUE™ (trofinetide) net sales of US$96.1 million, a 14% increase from Q2 2024 and Q1 2025.
Operational Achievements
A record number of patients in the US received DAYBUE shipments, marking the third consecutive quarter of growth. Acadia Pharmaceuticals completed the planned expansion of the DAYBUE sales force to drive future growth and initiated named patient supply programs in Europe, Israel, and the Rest of the World.
Royalty Income
Neuren earned A$14.7 million in Q2 2025 royalty income, up 16% from Q2 2024 and 9% from Q1 2025. Acadia reiterated its full-year 2025 DAYBUE US net sales guidance of US$380-405 million, implying full-year royalty income for Neuren between A$62-67 million.
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
